| 23.99 1.16 (5.08%) | 08-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.89 | 1-year : | 33.65 |
| Resists | First : | 25.59 | Second : | 28.8 |
| Pivot price | 23.03  |
|||
| Supports | First : | 20.39 | Second : | 16.97 |
| MAs | MA(5) : | 23.31 |
MA(20) : | 23.88 |
| MA(100) : | 21.53 |
MA(250) : | 22.81 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 47.5 |
D(3) : | 43.3 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 30 | Low : | 14.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KMTS ] has closed below upper band by 29.3%. Bollinger Bands are 17.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.26 - 24.38 | 24.38 - 24.48 |
| Low: | 22.91 - 23.05 | 23.05 - 23.16 |
| Close: | 23.79 - 24 | 24 - 24.18 |
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Mon, 03 Aug 2026
Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $178,511.04 in Stock - MarketBeat
Mon, 03 Aug 2026
Kestra Medical Technologies (KMTS) CBO sells 15,256 shares for tax withholding - Stock Titan
Mon, 03 Aug 2026
Kestra Medical Technologies (KMTS) CCO logs tax sell-to-cover trades - Stock Titan
Mon, 03 Aug 2026
Kestra Medical (KMTS) CFO sells 18,188 shares to cover RSU taxes - Stock Titan
Mon, 03 Aug 2026
Kestra Medical Technologies (KMTS) officer sells 22,229 shares for tax withholding - Stock Titan
Mon, 03 Aug 2026
Kestra Medical Technologies (KMTS) CEO reports 29,822 tax-cover sales - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 59 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 5.9 (%) |
| Held by Institutions | 102.5 (%) |
| Shares Short | 3,100 (K) |
| Shares Short P.Month | 2,930 (K) |
| EPS | -2.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.44 |
| Profit Margin | -138.4 % |
| Operating Margin | -137.4 % |
| Return on Assets (ttm) | -25.8 % |
| Return on Equity (ttm) | -56.6 % |
| Qtrly Rev. Growth | 66.1 % |
| Gross Profit (p.s.) | 0.83 |
| Sales Per Share | 1.62 |
| EBITDA (p.s.) | -2.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -82 (M) |
| Levered Free Cash Flow | -76 (M) |
| PE Ratio | -9.88 |
| PEG Ratio | 0 |
| Price to Book value | 5.39 |
| Price to Sales | 14.77 |
| Price to Cash Flow | -17.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|